Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Alpha Cognition Inc ACOGF


Primary Symbol: C.ACOG

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.


CSE:ACOG - Post by User

Post by culturedpiggy01on Jan 19, 2022 6:08pm
97 Views
Post# 34335115

$ACOG.v publishes updated corporate presentation

$ACOG.v publishes updated corporate presentation
$ACOG.v just published the updated version of their corporate presentation which includes latest information on all their projects. https://www.alphacognition.com/_resources/presentations/corporate-presentation.pdf?v=0.6

I suggest you check it out, it contains quite a few updates and new information like the latest in ALPHA-1062 - a patented, proposed treatment for mild-to-moderate Alzheimer’s Dementia and TBI’s (Traumatic Brain Injury). A lot of interesting stuff in there + investor considerations. Good to read 
 
td, $ACOG.v trading at $1.10 with market cap at $67.65 M
<< Previous
Bullboard Posts
Next >>